Precursor for radiolabelled DOTA-TOC
DOTA-TOC acetate; DOTA-[Tyr3]-octreotide; Edotreotide; CA index name: L-Cysteinamide, N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic(2→7)-disulfide, supplied as acetate salt
Sequence: DOTA-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr(ol), cyclic disulfide
Molar mass 1421.7 (net peptide)
CAS RN [204318-14-9]
Purity ≥ 98 %
- White to off-white powder
- Tested for bioburden and bacterial endotoxins.
CoA: appearance, HPLC (identity, purity, assay), GC (residual Solvents, water content, counter-ion), microbiology test
Forrer F. et al. Targeted radionuclide therapy with ⁹⁰Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res. 2006, 26, 703–707.
Koukouraki S. et al. Evaluation of the pharmacokinetics of ⁶⁸Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for ⁹⁰Y-DOTATOC therapy. Eur. J. Nucl. Med. Mol. Imaging 2006, 33, 460–466.
Add to inquiry
|Product||Product No.||Filling amount||Quantity|
|/products/chemicals/chemical/b1a33e38-4d76-4c06-9275-9baac76a7db4||Chemicals||Product No.: 9707|